spironolactone has been researched along with Leukemia in 1 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we evaluated the cytotoxic and NF-ĸB inhibition potential of new spiro(lactone-cyclohexanone) compounds in two different human leukemia cell lines (U937 and K562)." | 7.85 | Anti-proliferative, Cytotoxic and NF-ĸB Inhibitory Properties of Spiro(Lactone-Cyclohexanone) Compounds in Human Leukemia. ( Bachari, K; Bouhenna, MM; Diederich, M; Mameri, N; Orlikova, B; Pinto, DCGA; Schram, B; Silva, AMS; Taibi, N; Talhi, O, 2017) |
| " In this study, we evaluated the cytotoxic and NF-ĸB inhibition potential of new spiro(lactone-cyclohexanone) compounds in two different human leukemia cell lines (U937 and K562)." | 3.85 | Anti-proliferative, Cytotoxic and NF-ĸB Inhibitory Properties of Spiro(Lactone-Cyclohexanone) Compounds in Human Leukemia. ( Bachari, K; Bouhenna, MM; Diederich, M; Mameri, N; Orlikova, B; Pinto, DCGA; Schram, B; Silva, AMS; Taibi, N; Talhi, O, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouhenna, MM | 1 |
| Orlikova, B | 1 |
| Talhi, O | 1 |
| Schram, B | 1 |
| Pinto, DCGA | 1 |
| Taibi, N | 1 |
| Bachari, K | 1 |
| Diederich, M | 1 |
| Silva, AMS | 1 |
| Mameri, N | 1 |
1 other study available for spironolactone and Leukemia
| Article | Year |
|---|---|
Anti-proliferative, Cytotoxic and NF-ĸB Inhibitory Properties of Spiro(Lactone-Cyclohexanone) Compounds in Human Leukemia.
Topics: Biological Assay; Caspase 3; Caspase 7; Cell Death; Cell Proliferation; Cell Survival; Chromatograph | 2017 |